PCN70 MODELLING THE COST EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES VERSUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES IN METASTATIC COLORECTAL CANCER PATIENTS IN SWED ...
Abstract
Authors
C Holmberg R Aultman U Siebert E Sabate M Gyldmark